Ophthalmology

Journal Information
ISSN / EISSN : 0161-6420 / 1549-4713
Published by: Elsevier BV (10.1016)
Total articles ≅ 21,062
Current Coverage
SCOPUS
MEDICUS
MEDLINE
PUBMED
SCIE
Archived in
EBSCO
SHERPA/ROMEO
Filter:

Latest articles in this journal

Sidra Zafar, Oliver D. Schein,
Published: 24 January 2022
The publisher has not yet granted permission to display this abstract.
Anh D. Bui, Christina L. Kong, , S.R. Rathinam, John A. Gonzales, Radhika Thundikandy, Anuradha Kanakath, Bala Murugan, R. Vedhanayaki, Lyndell L. Lim, et al.
Published: 24 January 2022
The publisher has not yet granted permission to display this abstract.
Nicolaas P. DeRuyter, , Qingxia Chen, Henry Leder, Ella Leung, Rahul Reddy, Jill Blim, Carl C. Awh, Paul Hahn
Published: 23 January 2022
, Tatyana Milman, , Lauren A. Dalvin, Charles G. Eberhart, Christopher M. Heaphy, , Chun-Chieh Lin, Philip W. Dockery, Jerry A. Shields, et al.
Published: 23 January 2022
The publisher has not yet granted permission to display this abstract.
, Veeral Sheth, Sam E. Mansour, Brandon Coughlin, Victor H. Gonzalez
Published: 18 January 2022
Abstract:
Objective To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN®) in patients with diabetic macular edema (DME) Design Three-year, phase 4, non-randomized, open-label observational study Participants Patients with DME who previously received corticosteroid treatment without a clinically significant rise in intraocular pressure (IOP) (All eyes n=202 eyes in 159 patients; 36-month completers n=94 eyes) Methods A prospective, observational study in which patients received a 0.19-mg FAc intravitreal implant at baseline and were then observed for safety-, visual-, anatomical-, and treatment burden-related outcomes for up to 36 months Main Outcome Measures Primary safety outcomes included changes in IOP and interventions to manage IOP elevations. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and adjunctive DME treatment frequency Results At 36 months post FAc implant, study eyes had a mean BCVA increase of 3.61 letters (P-value = 0.0222) and mean CST decrease of 60.69 μm (P-value< 0.0001) compared to baseline. Overall median treatment frequency decreased from 3.4 treatments/year in the 36 months pre FAc implant to 1 treatment/year in the 36 months post FAc implant, a treatment burden reduction of 67.6%. Furthermore, among the 36-month completer group (n = 94 eyes), 25.53% of eyes remained treatment free through 36 months. Mean IOP remained stable throughout the study, and IOP increases to > 30 mmHg occurred in 10.89% of eyes. IOP-related procedures were infrequent, with a surgical rate of 2.97% with 1.49% attributable to steroid (vs surgeries attributable primarily to neovascular glaucoma). In addition, an IOP response below 25 mmHg after the steroid challenge predicted that 96.92% of eyes would have a similar outcome to 0.19-mg FAc implant at the last visit. IOP increases that did occur were manageable with standard treatments (n = 202 eyes). Conclusions In patients with DME, the 0.19-mg FAc implant provided improved visual outcomes and reduced treatment burden compared with previous treatments while maintaining a favorable safety profile.
Jian Xiong, Fei Li,
Published: 17 January 2022
The publisher has not yet granted permission to display this abstract.
, Siying Li, Lynn Liu, , David W. Parke, George A. Williams
Published: 15 January 2022
The publisher has not yet granted permission to display this abstract.
Kelsey A. Roelofs, Gary Duckwiler, Bradley Gundlach, Bryan Yoo, Stefania B. Diniz, Liza M. Cohen, Robert A. Goldberg,
Published: 11 January 2022
The publisher has not yet granted permission to display this abstract.
Back to Top Top